Barrington analyst Michael Petusky has maintained their neutral stance on LMAT stock, giving a Hold rating today.
Michael Petusky has given his Hold rating due to a combination of factors influencing Lemaitre Vascular’s financial performance and future outlook. The company reported a solid revenue increase, surpassing both the firm’s and consensus estimates, with notable growth in key product categories such as grafts and carotid shunts. However, the earnings per share (EPS) fell short of expectations, and the adjusted EBITDA also came in below the firm’s estimates.
Despite the positive revenue growth, the company’s updated guidance for fiscal year 2025 indicates a reduction in the expected EPS range, suggesting a potential slowdown in operating margin expansion compared to previous years. While Lemaitre Vascular’s balance sheet remains strong with significant cash reserves and improved free cash flow, the modest margin expansion anticipated for 2025 has led to the decision to maintain a Hold rating, reflecting a cautious stance on the stock’s near-term performance.
Petusky covers the Healthcare sector, focusing on stocks such as SurModics, Option Care Health, and Lemaitre Vascular. According to TipRanks, Petusky has an average return of 1.4% and a 44.31% success rate on recommended stocks.